S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
NASDAQ:ADXS

Advaxis - ADXS Stock Forecast, Price & News

$2.10
-0.01 (-0.47%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.01
$2.16
50-Day Range
N/A
52-Week Range
$1.00
$11.52
Volume
6,336 shs
Average Volume
10,529 shs
Market Capitalization
$3.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Advaxis

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter.

ADXS Stock News Headlines

Advaxis (NASDAQ:ADXS) Coverage Initiated at StockNews.com
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter.

ADXS Company Calendar

Today
2/04/2023
Fiscal Year End
10/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADXS
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-17,860,000.00
Pretax Margin
-6,064.80%

Debt

Sales & Book Value

Annual Sales
$3.24 million
Book Value
$21.36 per share

Miscellaneous

Free Float
1,810,000
Market Cap
$3.81 million
Optionable
Not Optionable
Beta
2.44

Key Executives

  • Ken Berlin
    President, Chief Executive Officer & Director
  • Igor Gitelman
    VP-Finance, Chief Financial & Accounting Officer
  • Andres A. Gutiérrez
    Chief Medical Officer & Executive Vice President
  • Michael Grace
    Vice President-Technical Operations













ADXS Stock - Frequently Asked Questions

How have ADXS shares performed in 2023?

Advaxis' stock was trading at $1.90 at the beginning of 2023. Since then, ADXS shares have increased by 10.5% and is now trading at $2.10.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Advaxis own?
What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How do I buy shares of Advaxis?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $2.10.

How much money does Advaxis make?

Advaxis (NASDAQ:ADXS) has a market capitalization of $3.81 million and generates $3.24 million in revenue each year. The company earns $-17,860,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis.

How can I contact Advaxis?

Advaxis' mailing address is 9 DEER PARK DRIVE SUITE K-1, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.advaxis.com. The company can be reached via phone at (609) 452-9813, via email at tim@lifesciadvisors.com, or via fax at 609-452-9818.

This page (NASDAQ:ADXS) was last updated on 2/5/2023 by MarketBeat.com Staff